Randomised, Double-Blind, Parallel-Group, Placebo-Controlled, and Active Referenced Study of Lu AA34893 to Evaluate the Efficacy and Safety of Three Doses Lu AA34893 in the Treatment of Depression in Patients With Bipolar I or II Disorder
Phase of Trial: Phase II
Latest Information Update: 28 Feb 2017
At a glance
- Drugs LU AA34893 (Primary) ; Quetiapine
- Indications Bipolar I disorders; Bipolar II disorders
- Focus Therapeutic Use
- 03 Jul 2012 Actual initiation date (28 Nov 2007) added as reported by European Clinical Trials Database record.
- 24 Sep 2010 Status changed from suspended to discontinued as reported by ClinicalTrials.gov.
- 24 Sep 2010 Last checked against ClinicalTrials.gov record.